ArticlePloS one2025
Assessing the global burden of Type 2 diabetes in women of reproductive age.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- First-trimester preexisting diabetes screening in Medicaid beneficiaries.Pregnancy (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research critically assesses the global prevalence and trends of Type 2 diabetes (T2D) among women of reproductive age (15-39 years) spanning the period from 1990 to 2021. We conducted an analysis of the age-standardized incidence rates (ASIR), Disability-Adjusted Life Years (DALYs), and Estimated Annual Percentage Change (EAPC) using data from the Global Burden of Diseases (GBD) Study 2021. The global ASIR and DALYs per 100,000 among reproductive-aged women increased from 101.01 to 205.17 and from 113.25 to 198.41, respectively. The EAPC for ASIR was 2.32 [95% Confidence Interval (CI): 2.25 to 2.39], and that for DALYs was 1.76 (95% CI: 1.69 to 1.83), both indicating an upward trend. The increase in T2D prevalence was more prominent in the 25-29 age group and younger women. According to Socio-demographic Index (SDI) category, the highest ASIR and age-standardized DALY rate were observed in low-middle SDI regions (ASIR 104.44; age-standardized DALY rate 136.78). The most significant increases in ASIR were recorded in High-income North America (EAPC = 3.64, 95% CI 3.46 to 3.82) and Cameroon (EAPC = 4.30, 95% CI 4.14 to 4.46). In terms of age-standardized DALY rates, the steepest rises were seen in East Asia (EAPC = 2.71, 95% CI 2.34 to 3.08) and Turkmenistan (EAPC = 4.21, 95% CI 3.89 to 4.52). This study shows a remarkable increase in global T2D burden in women of reproductive age between 1990 and 2021. Interventions should be targeted towards women aged 25-29 years and lifestyle risk factors in low-middle SDI, specifically in countries in North Africa and the Middle East, East Asia, Oceania.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.